offline
Insmed stock shoots up 18% after company says it expects drug Arikayce to bring in $9.8 million in fourth quarter
By SARAH TOY
Shares of Insmed Incorporated INSM, +18.52% shot up 18% in after-hours trading Friday after the company announced it expected sales of its antibacterial Arikayce to be $9.8 million for the fourth quarter, with $9.2 million in U.S. sales and $600,000 in sales outside the U.S. The drug is used to treat patients with a lung disease caused by a group of bacteria called Mycobacterium avium complex (MAC) and who do not respond to traditional treatment.
...
https://www.marketwatch.com/story/shares...2019-01-04
ist auf dem chart noch nicht zu sehen....
![[Bild: INSMc1dl1649.png]](https://finviz.com/publish/010419/INSMc1dl1649.png)
By SARAH TOY
Shares of Insmed Incorporated INSM, +18.52% shot up 18% in after-hours trading Friday after the company announced it expected sales of its antibacterial Arikayce to be $9.8 million for the fourth quarter, with $9.2 million in U.S. sales and $600,000 in sales outside the U.S. The drug is used to treat patients with a lung disease caused by a group of bacteria called Mycobacterium avium complex (MAC) and who do not respond to traditional treatment.
...
https://www.marketwatch.com/story/shares...2019-01-04
ist auf dem chart noch nicht zu sehen....
